Silver Book Fact

32 drugs are currently in development for Parkinson’s disease.

PhRMA. 2008 Report: Medicines in Development for Older Americans; November 2008

Reference

Title
2008 Report: Medicines in Development for Older Americans
Publication Date
November 2008
Authors
PhRMA

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.  
  • Impact of a 5-Year Delay in Onset by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Current research supported by the National Institute of Neurological Disease Orders and Stroke (NINDS) at NIH is using animal models to study progression of the disease and develop new drugs…  
  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.